Aradigm Corporation Company Profile (NASDAQ:ARDM)

About Aradigm Corporation (NASDAQ:ARDM)

Aradigm Corporation logoAradigm Corporation is a pharmaceutical company focused on the development and commercialization of products for the treatment and prevention of severe respiratory diseases. The Company's lead product candidate is Pulmaquin inhaled ciprofloxacin, which is in Phase III clinical trials. It offers AERx pulmonary drug delivery platform and other technologies. Its partnered programs under development include Inhaled Ciprofloxacin. It is also engaged in developing Smoking Cessation Therapy (ARD-1600 Inhaled Nicotine). Its lead development candidates are its formulations of the potent antibiotic ciprofloxacin (Pulmaquin (ARD-3150) and Lipoquin (ARD-3100)) that are delivered by inhalation for the management of infections associated with the severe respiratory diseases, such as cystic fibrosis (CF) and non-cystic fibrosis bronchiectasis (BE). Pulmaquin uses slow release liposomal formulation (Lipoquin) mixed with a small amount of ciprofloxacin dissolved in an aqueous medium.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:ARDM
  • CUSIP: N/A
  • Web:
  • Market Cap: $77.22 million
  • Outstanding Shares: 14,430,000
Average Prices:
  • 50 Day Moving Avg: $2.59
  • 200 Day Moving Avg: $1.64
  • 52 Week Range: $0.78 - $6.87
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -12.03
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $9.54 million
  • Price / Sales: 7.28
  • Book Value: ($0.42) per share
  • Price / Book: -11.45
  • EBITDA: ($14,990,000.00)
  • Net Margins: -196.65%
  • Return on Equity: -665.03%
  • Return on Assets: -83.01%
  • Debt-to-Equity Ratio: -2.34%
  • Current Ratio: 2.52%
  • Quick Ratio: 2.52%
  • Average Volume: 350,034 shs.
  • Beta: 1.56
  • Short Ratio: 1.39

Frequently Asked Questions for Aradigm Corporation (NASDAQ:ARDM)

What is Aradigm Corporation's stock symbol?

Aradigm Corporation trades on the NASDAQ under the ticker symbol "ARDM."

How were Aradigm Corporation's earnings last quarter?

Aradigm Corporation (NASDAQ:ARDM) released its earnings results on Thursday, August, 10th. The company reported $0.07 EPS for the quarter, topping analysts' consensus estimates of ($0.30) by $0.37. The firm had revenue of $7.68 million for the quarter. Aradigm Corporation had a negative return on equity of 665.03% and a negative net margin of 196.65%. View Aradigm Corporation's Earnings History.

When will Aradigm Corporation make its next earnings announcement?

Aradigm Corporation is scheduled to release their next quarterly earnings announcement on Wednesday, November, 8th 2017. View Earnings Estimates for Aradigm Corporation.

Where is Aradigm Corporation's stock going? Where will Aradigm Corporation's stock price be in 2017?

1 analysts have issued 1-year target prices for Aradigm Corporation's stock. Their forecasts range from $10.00 to $10.00. On average, they expect Aradigm Corporation's stock price to reach $10.00 in the next year. View Analyst Ratings for Aradigm Corporation.

Who are some of Aradigm Corporation's key competitors?

Who are Aradigm Corporation's key executives?

Aradigm Corporation's management team includes the folowing people:

  • Virgil D. Thompson, Independent Chairman of the Board
  • Igor Gonda Ph.D., President, Chief Executive Officer, Director
  • Nancy E. Pecota, Chief Financial Officer, Vice President - Finance
  • Juergen Froehlich, Chief Medical Officer
  • David Bell, Director
  • Frederick M. Hudson CPA, Independent Director
  • John M. Siebert Ph.D., Independent Director

How do I buy Aradigm Corporation stock?

Shares of Aradigm Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Aradigm Corporation's stock price today?

One share of Aradigm Corporation stock can currently be purchased for approximately $4.81.

MarketBeat Community Rating for Aradigm Corporation (NASDAQ ARDM)
Community Ranking:  1.7 out of 5 (star)
Outperform Votes:  60 (Vote Outperform)
Underperform Votes:  119 (Vote Underperform)
Total Votes:  179
MarketBeat's community ratings are surveys of what our community members think about Aradigm Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Aradigm Corporation (NASDAQ:ARDM) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Buy Rating
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $10.00 (107.90% upside)
Consensus Price Target History for Aradigm Corporation (NASDAQ:ARDM)
Price Target History for Aradigm Corporation (NASDAQ:ARDM)
Analysts' Ratings History for Aradigm Corporation (NASDAQ:ARDM)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/25/2017Ladenburg Thalmann Financial ServicesReiterated RatingBuy$7.50 -> $10.00MediumView Rating Details
(Data available from 10/17/2015 forward)


Earnings History for Aradigm Corporation (NASDAQ:ARDM)
Earnings by Quarter for Aradigm Corporation (NASDAQ:ARDM)
Earnings History by Quarter for Aradigm Corporation (NASDAQ ARDM)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2017($0.31)N/AView Earnings Details
8/10/2017Q2 2017($0.30)$0.07$7.68 millionViewN/AView Earnings Details
5/15/2017Q1 2017($0.43)($0.25)$1.69 millionViewN/AView Earnings Details
3/28/2017Q4 2016($0.37)($0.54)$0.13 millionViewN/AView Earnings Details
11/9/2016Q3 2016($0.53)($0.55)$0.05 millionViewN/AView Earnings Details
8/10/2016Q2($0.59)($0.59)$0.01 millionViewN/AView Earnings Details
5/10/2016Q1($0.59)($0.55)$0.01 millionViewN/AView Earnings Details
3/15/2016Q415($0.55)($0.63)$0.04 millionViewN/AView Earnings Details
11/11/2015Q3($0.19)($0.38)$4.67 millionViewN/AView Earnings Details
8/13/2015Q2($0.08)($0.08)$11.60 million$10.00 millionViewN/AView Earnings Details
5/11/2015Q1($0.06)($0.08)$8.77 millionViewN/AView Earnings Details
3/17/2015Q414($0.07)($0.06)$6.70 million$8.10 millionViewN/AView Earnings Details
11/7/2014Q314($0.10)($0.06)$4.80 million$6.60 millionViewN/AView Earnings Details
8/7/2014Q214($0.09)($0.09)$4.25 million$12.20 millionViewN/AView Earnings Details
10/28/2013Q3 13($0.04)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Aradigm Corporation (NASDAQ:ARDM)
Current Year EPS Consensus Estimate: $-0.74 EPS
Next Year EPS Consensus Estimate: $-0.4 EPS


Dividend History for Aradigm Corporation (NASDAQ:ARDM)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Aradigm Corporation (NASDAQ:ARDM)
Insider Ownership Percentage: 7.30%
Institutional Ownership Percentage: 33.64%
Insider Trades by Quarter for Aradigm Corporation (NASDAQ:ARDM)
Institutional Ownership by Quarter for Aradigm Corporation (NASDAQ:ARDM)
Insider Trades by Quarter for Aradigm Corporation (NASDAQ:ARDM)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
4/4/2017Juergen Kurt FroehlichInsiderSell3,765$1.51$5,685.15View SEC Filing  
10/4/2016Juergen Kurt FroehlichInsiderSell423$6.76$2,859.48View SEC Filing  
6/21/2016Juergen Kurt FroehlichInsiderSell333$4.45$1,481.85View SEC Filing  
12/13/2013Virgil ThompsonDirectorSell3,340$0.17$567.80View SEC Filing  
8/27/2013First Eagle Investment ManagemMajor ShareholderBuy40,322,580$0.12$4,838,709.60View SEC Filing  
12/11/2012First Eagle Investment ManagemMajor ShareholderBuy41,666,667$0.12$5,000,000.04View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Aradigm Corporation (NASDAQ:ARDM)
Latest Headlines for Aradigm Corporation (NASDAQ:ARDM)
DateHeadline logoReviewing Paratek Pharmaceuticals (PRTK) and Aradigm Corporation (ARDM) - October 13 at 8:26 AM logoAradigm Regains Compliance with NASDAQ Listing Requirements - October 10 at 5:21 PM logoNew Research Coverage Highlights Aradigm, Social Reality Inc, Rentech, PayPal, JPMorgan Chase, and Helios and Matheson Analytics ­Consolidated Revenues, Company Growth, and Expectations - October 10 at 5:21 PM logoCan Aradigm Corporation (ARDM) Improve Your Portfolio Returns? - October 9 at 4:58 PM logoAradigm Announces FDA Acceptance of NDA for Linhaliq with Priority Review Status - October 2 at 3:54 PM logoCorporate News Blog - Aradigm Announces FDA Acceptance of Priority Review Status for its NDA for Linhaliq - October 2 at 3:54 PM logoAradigm, NDA for Linhaliq Accepted by FDA With Priority Review, Catalyst and Pipeline Review - October 2 at 3:54 PM logoContrasting Aradigm Corporation (ARDM) & Its Competitors - September 28 at 6:22 AM logoU.S. Futures Cautiously Lower Ahead of Speakers, Data - September 27 at 7:56 PM logoPro-Trader Daily: Corporate News Blog - Aradigm Announces FDA Acceptance of Priority Review Status for its NDA for Linhaliq - September 27 at 7:56 PM logoAradigm Corp. (ARDM) Announces FDA Accepts Linhaliq NDA with Priority Review Status - September 27 at 7:56 PM logoAradigm Corporation (ARDM) Presents At Ladenburg Thalmann 2017 Healthcare Conference - Slideshow - September 27 at 7:56 PM logoAradigm Corporation (ARDM) Receives "Buy" Rating from Ladenburg Thalmann Financial Services - September 25 at 6:00 PM logo20 Biggest Mid-Day Gainers For Monday - September 25 at 1:40 PM logoAradigm to Present at the Ladenburg Thalmann 2017 Healthcare Conference on September 26 - September 22 at 1:25 PM logoAradigm to Host KOL Call on Infection Management in Non-Cystic Fibrosis Bronchiectasis Patients - September 15 at 4:22 PM logoAradigm Announces Upcoming Data Presentations in Non-Cystic Fibrosis Bronchiectasis at the European Respiratory Society (ERS) 2017 Annual Congress - September 5 at 5:40 PM logoBoxer Capital, LLC Buys Macrogenics Inc, G1 Therapeutics Inc, iPath S&P 500 VIX Short Term ... - August 15 at 4:59 PM logoAradigm Awarded NIH Grant to Investigate the Treatment of Pulmonary Non-Tuberculous Mycobacterial (PNTM) Infections with Linhaliq - August 15 at 4:59 PM logoAradigm Corporation (NASDAQ:ARDM) Releases Quarterly Earnings Results, Beats Estimates By $0.37 EPS - August 11 at 2:42 PM logoAradigm Announces Second Quarter 2017 Financial Results - August 10 at 5:26 PM logoAradigm posts 2Q profit - August 10 at 5:26 PM logoAradigm Corporation (NASDAQ:ARDM) to Release Earnings on Tuesday - August 1 at 7:17 AM logoAradigm Corp. (ARDM) Submits NDA for U.S. Marketing Approval of Linhaliq in Non-Cystic Fibrosis Bronchiectasis - July 29 at 8:45 PM logoAradigm Submits New Drug Application (NDA) to FDA for U.S. Marketing Approval of Linhaliq in Non-Cystic Fibrosis Bronchiectasis - July 27 at 4:05 PM
News IconBRIEF-Aradigm Corp presents analysis of results for phase 3 orbit-3, orbit-4 clinical trials - July 8 at 3:41 PM logoQuietly, Spanish company makes fifth Bay Area biotech investment in 4 years - July 8 at 6:22 AM logoARADIGM CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits - March 30 at 9:04 PM logoAradigm Announces Fourth Quarter 2016 and Full Year Financial Results - March 28 at 3:37 PM logoARADIGM CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits - December 6 at 12:40 PM logoAradigm's Inhaled Antibiotic Fails Study (ARDM) - December 3 at 8:44 AM logoAradigm Lung Infection Antibiotic Fails Trial (ARDM) - December 2 at 9:01 PM logoAradigm Announces Top-Line Results from Two Phase 3 Studies Evaluating Pulmaquin for the Chronic Treatment of Non-Cystic Fibrosis Bronchiectasis Patients with Lung Infections ... - December 1 at 3:41 PM logoMid-Day Market Update: Crude Oil Up Over 4%; Express Shares Fall On Weak Outlook - December 1 at 3:41 PM logo7:03 am Aradigm announces top-line results from its two Phase 3 clinical trials evaluating the safety and efficacy of Pulmaquin (shares halted) - December 1 at 3:41 PM logoAradigm Corp. drops 54% in pre-market trade on results of two late-stage clinical trials - December 1 at 3:41 PM logoAradigm Shares Plunge After Releasing Mixed Clinical Trial Results For Pulmaquin - December 1 at 3:41 PM logoWhat's In The Offing For These Biotech Stocks? - November 22 at 12:39 PM logoMulti-million Dollar DTRA Funding for Biodefense Research with Aradigm’s Inhaled Ciprofloxacin - October 18 at 8:23 AM logoARDM Awaits Data In Q4, FDA Clears TCMD Device, Newfound Interest For GLMD, GALT - September 23 at 8:24 AM logoAradigm (ARDM) Shares March Higher, Can It Continue? - September 22 at 9:26 AM logoARADIGM CORP Files SEC form 8-K, Submission of Matters to a Vote of Security Holders - June 10 at 5:02 PM



Aradigm Corporation (ARDM) Chart for Tuesday, October, 17, 2017

This page was last updated on 10/17/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.